Could an asthma drug shield young hearts and kidneys from diabetes damage?
NCT ID NCT07409714
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether montelukast, a medicine used for asthma, can help protect the kidneys and blood vessels in 50 teens and young adults (ages 14-24) with type 2 diabetes. The drug works by blocking harmful inflammatory chemicals linked to diabetes complications. Researchers will measure changes in kidney blood flow and artery health over 6 months to see if this approach could reduce long-term risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.